Table 1. Clinicopathological characteristics of patients.
| Characteristics | Chemotherapy | P value | |
| Receiving (N/%) | Refusal (N/%) | ||
| Age | <0.001 | ||
| 70–74 | 143(63.3) | 66 (41.2) | |
| 75–79 | 67(29.6) | 61 (38.2) | |
| 80–95 | 16(7.1) | 33 (20.6) | |
| Gender | <0.001 | ||
| Male | 165 (73.0) | 87 (54.4) | |
| Female | 61 (27.0) | 73 (45.6) | |
| Location | 0.081 | ||
| Rectum | 104(46.1) | 76 (47.5) | |
| Sigmoid | 56 (24.8) | 38 (23.7) | |
| Descending | 11 (4.8) | 7 (4.4) | |
| Transverse | 11 (4.8) | 11 (4.8) | |
| Ascending | 44 (19.5) | 28 (17.5) | |
| Pathology grade | 0.712 | ||
| G1 | 10 (4.5) | 5 (3.2) | |
| G2 | 178 (78.7) | 128 (80.0) | |
| G3 | 38 (16.8) | 27 (16.8) | |
| Stage | 0.333 | ||
| II B | 87 (38.5) | 80 (50.0) | |
| III | 84 (37.1) | 48 (30.0) | |
| VI | 55 (24.4) | 32 (20.0) | |
| Regimen | <0.001 | ||
| 5-FU/LV | 19 (8.4) | ||
| Oral drug | 90 (40.0) | ||
| FOLFOX | 45 (19.9) | ||
| XELOX | 67 (29.6) | ||
| FOLFIRI | 5 (2.1) | ||
| Living | 0.003 | ||
| YES | 157 (69.5) | 99 (61.8) | |
| NO | 69 (30.5) | 61 (38.2) | |
| Complication | <0.001 | ||
| Yes | 13 (5.8) | 35 (21.8) | |
| No | 213 (94.2) | 125 (78.2) | |
| BSA | <0.001 | ||
| Mean | 1.59 | 1.48 | |
| BMI | 0.004 | ||
| Mean | 26.59 | 20.96 | |
Oral drug: xeloda/UFT; FOLFOX: 5-FU/LV+oxaliplatin; XELOX: xeloda+oxaliplatin; FOLFIRI: 5-FU/LV+irinotecan; LV = leucovorin.